This phase 2 study tests whether adding a new drug called BRII-835 to standard pegylated interferon alpha can help people with chronic hepatitis B lose a key virus marker (HBsAg) from their blood. About 86 adults aged 18-60 who have been on antiviral therapy for at least 6 months…
Phase: PHASE2 • Sponsor: Brii Biosciences Limited • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC